Actively Recruiting
Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)
Led by University Hospital, Bordeaux · Updated on 2025-03-21
150
Participants Needed
7
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Thrombo-embolic venous diseases are represented by deep venous thrombosis and/or pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis in unusual sites, the etiological workup remains negative, which represents a problem for the management of the anticoagulant treatments. Recently, two factors have been identified as important in the physiopathology of hemostasis and coagulation: the presence of clonal hematopoiesis of indetermined potential (CHIP) and the formation of neutrophil extracellular traps (NETs). In this study, these two factors will be studied in patients with repeated venous thrombosis or thrombosis occurring in unusual site.
CONDITIONS
Official Title
Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients under 50 years old (male or female)
- History of splanchnic venous thrombosis or cerebral venous thrombosis
- History of venous thrombosis of the upper limb
- History of unprovoked pulmonary embolism (1st episode if male, 2nd episode if female)
- History of one deep vein thrombosis episode plus one arterial thrombosis episode
You will not qualify if you...
- Surgery within 3 months before the qualifying thrombotic episode
- Lower limb fracture with immobilization longer than 3 days within 3 months before the qualifying thrombotic episode
- Use of estro-progestational contraception
- Pregnancy
- Immobilization for acute medical reasons within 3 months before the qualifying thrombotic episode
- Air or car travel longer than 6 hours
- Presence of active cancer (solid or hematologic)
- Chronic inflammatory digestive or joint diseases
- Ongoing treatment with heparin (LMWH or UFH)
- Abnormalities in thrombophilia tests including Protein C deficiency, Protein S deficiency, Anti-thrombin deficiency, Factor II or Factor V mutations
- Presence of anti-phospholipid syndrome
- Presence of myeloproliferative neoplasia
- Presence of paroxysmal nocturnal hemoglobinuria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
CHU de Bordeaux, Service de Neurologie
Bordeaux, France
Not Yet Recruiting
2
CHU de Bordeaux, Service Gastro-Entérologie
Bordeaux, France
Not Yet Recruiting
3
CHU de Bordeaux, Service Hématologie Biologique
Bordeaux, France
Actively Recruiting
4
CHU de Bordeaux, Service Médecine Vasculaire
Bordeaux, France
Actively Recruiting
5
CHU de Bordeaux, Unité ambulatoire de Médecine Vasculaire
Bordeaux, France
Actively Recruiting
6
CHU de Lille, Service Hémostase Clinique
Lille, France
Not Yet Recruiting
7
APHM - Hôpital de la Timone, Service Hématologie
Marseille, France
Not Yet Recruiting
Research Team
A
Alexandre GUY
CONTACT
C
Chloé JAMES
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here